Research press release


Nature Communications

Gene therapy: Taking it to heart



今回、Lucie Carrierたちは、ヒト新生児肥大型心筋症に似た症状を示すように遺伝子工学的に作製されたマウスに対して、長期遺伝子治療が有効なことを明らかにした。変異していない遺伝子の情報をマウスの心臓細胞に送達するように遺伝子操作されたウイルスの単回投与を行った実験で、34週間の観察期間中、肥大型心筋症の症状が発現しなかったのだ。また、この治療法は、肥大型心筋症の発症に関与すると考えられる変質タンパク質を発生させる変異型mRNA種の産生を抑制するという結論も得られた。


The first successful long-term gene therapy for neonatal hypertrophic cardiomyopathy (HCM), demonstrated in a mouse model, is reported online this week in Nature Communications. HCM is the most prevalent inherited cardiac disease, with an estimated frequency of 1 in 500.

HCM is caused by mutations in genes encoding components of the heart muscles. The disease can lead to sudden cardiac death in young adults, particularly athletes, and some patients go on to develop severe systolic dysfunction and heart failure. In newborns, HCM can rapidly evolve into systolic heart failure and death within the first year of life.

Lucie Carrier and colleagues show successful, long-term gene therapy in mice that have been engineered to genetically mimic human neonatal cardiomyopathies. A single administration of a modified virus, which delivers non-mutated genetic information into heart cells of mice, seems to prevent the symptoms of HCM from occurring during a 34 week observation period. In addition, the therapy also seems to suppress the production of mutant mRNA species, which can give rise to malformed proteins that are thought to be involved the development of the disease.

This finding, in mice, suggests that gene therapy may become a realistic treatment option for severe neonatal HCM, which is currently untreatable aside from heart transplantation. However, further trials are necessary to determine the safety and efficacy of this therapy in humans.

doi: 10.1038/ncomms6515

「Nature 関連誌注目のハイライト」は、ネイチャー広報部門が報道関係者向けに作成したリリースを翻訳したものです。より正確かつ詳細な情報が必要な場合には、必ず原著論文をご覧ください。

メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週最新のNature 関連誌のハイライトを皆様にお届けいたします。